{"id":870089,"date":"2025-08-04T12:42:59","date_gmt":"2025-08-04T16:42:59","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/hyperfine-achieves-clinical-milestone-ahead-of-plan-with-100th-patient-enrolled-in-neurology-office-study-using-the-next-generation-swoop-system\/"},"modified":"2025-08-04T12:42:59","modified_gmt":"2025-08-04T16:42:59","slug":"hyperfine-achieves-clinical-milestone-ahead-of-plan-with-100th-patient-enrolled-in-neurology-office-study-using-the-next-generation-swoop-system","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/hyperfine-achieves-clinical-milestone-ahead-of-plan-with-100th-patient-enrolled-in-neurology-office-study-using-the-next-generation-swoop-system\/","title":{"rendered":"Hyperfine Achieves Clinical Milestone Ahead of Plan With 100th Patient Enrolled in Neurology Office Study Using the Next-Generation Swoop\u00ae System"},"content":{"rendered":"

<\/p>\n

Hyperfine Achieves Clinical Milestone Ahead of Plan With 100th Patient Enrolled in Neurology Office Study Using the Next-Generation Swoop\u00ae System<\/b><\/p>\n

NEURO PMR study evaluates the clinical utility and patient experience of AI-powered portable MRI in an outpatient setting<\/i><\/p>\n

GUILFORD, Conn.–(BUSINESS WIRE<\/a>)–Hyperfine, Inc.<\/a> (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared AI-powered portable MRI system for the brain\u2014the Swoop\u00ae system\u2014 today announced the successful enrollment of 100 patients in its NEURO PMR (Neurological Evaluation in the Office with Portable MRI) study just 16 weeks after the study initiation, announced on April 15, 2025. This milestone reflects strong clinician enthusiasm for accessible, point-of-care brain imaging and supports Hyperfine’s market expansion into outpatient neurology offices.<\/p>\n

This press release features multimedia. View the full release here: https:\/\/www.businesswire.com\/news\/home\/20250804516616\/en\/<\/a><\/p>\n

\"\"<\/div>\n

\nThe NEURO PMR study, being conducted at DENT Neurologic Institute and Texas Neurology, is the first multi-center, prospective observational study comparing portable ultra-low-field MRI with conventional high-field MRI in neurology office settings. All patients enrolled in the study have been scanned on the next-generation Swoop\u00ae system powered by OptiveAI\u2122 software, with results expected to be announced in early 2026.<\/p>\n

\nDr. Laszlo Mechtler, Chief Medical Officer at DENT Neurologic Institute and the study’s Principal Investigator, stated, \u201cThe next-generation Swoop\u00ae system delivers impressive image quality with a simplified clinic workflow and comfortable patient experience. The promise of this technology is that it puts brain imaging back into the hands of neurologists\u2014by providing an affordable, easy-to-operate portable MRI system that fits seamlessly into a clinic setting without expensive siting costs.”<\/p>\n

\nThis milestone supports Hyperfine\u2019s commercial launch in the neurology office market, following the successful conclusion of its office pilot program. In the pilot, early neurology practices acquired and implemented Swoop\u00ae systems in their clinic, completed IAC accreditation, and obtained reimbursement from CMS and private insurers. To drive commercial adoption, Hyperfine has also entered into a strategic partnership with NeuroNet Pro, the largest U.S. association of independent neurology practices, to bring greater awareness and practice support for their portable MRI technology.<\/p>\n

\n\u201cNeurologists typically order between 500 and 600 brain MRIs each year, yet only 5% of private neurology offices have in-house imaging,” said Maria Sainz, President and CEO of Hyperfine. “Our next-generation Swoop\u00ae system delivers an exciting opportunity for independent practices\u2014expanding access to advanced imaging, boosting clinic efficiency, and elevating the level of patient care.\u201d<\/p>\n

\nFor more information about the Swoop\u00ae system and Optive AI\u2122 software, please visit HyperfineMRI.com<\/a>.<\/p>\n

About the Swoop\u00ae AI-Powered Portable MRI (V2) System
\n
<\/b>The Swoop\u00ae Portable MR Imaging\u00ae (V2) System is U.S. Food and Drug Administration (FDA) cleared for brain imaging of patients of all ages. It is a portable, ultra-low-field magnetic resonance imaging device for producing images that display the internal structure of the head where full diagnostic examination is not clinically practical. When interpreted by a trained physician, these images provide information that can be useful in determining a diagnosis.<\/p>\n

About Hyperfine, Inc.
\n
<\/b>Hyperfine, Inc. (Nasdaq: HYPR) is the groundbreaking health technology company that has redefined brain imaging with the Swoop\u00ae system\u2014the first FDA-cleared, portable, ultra-low-field, magnetic resonance brain imaging system capable of providing imaging at multiple points of professional care. The mission of Hyperfine, Inc. is to revolutionize patient care globally through transformational, accessible, clinically relevant diagnostic imaging. Founded by Dr. Jonathan Rothberg in a technology-based incubator called 4Catalyzer, Hyperfine, Inc. scientists, engineers, and physicists developed the Swoop\u00ae system out of a passion for redefining brain imaging methodology and how clinicians can apply accessible diagnostic imaging to patient care. For more information, visit HyperfineMRI.com<\/a>.<\/p>\n

\nThe Hyperfine logo, Swoop, and Portable MR Imaging are registered trademarks of Hyperfine, Inc. The Swoop logo, Optive AI logo, and Optive AI are trademarks of Hyperfine, Inc.<\/p>\n

Forward-Looking Statements
\n
<\/b>This press release includes \u201cforward-looking statements\u201d within the meaning of the \u201csafe harbor\u201d provisions of the Private Securities Litigation Reform Act of 1995. Actual results of Hyperfine, Inc. (the \u201cCompany\u201d) may differ from its expectations, estimates and projections and consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as \u201cexpect,\u201d \u201cestimate,\u201d \u201cproject,\u201d \u201cbudget,\u201d \u201cforecast,\u201d \u201canticipate,\u201d \u201cintend,\u201d \u201cplan,\u201d \u201cmay,\u201d \u201cwill,\u201d \u201ccould,\u201d \u201cshould,\u201d \u201cbelieves,\u201d \u201cpredicts,\u201d \u201cpotential,\u201d \u201ccontinue,\u201d and similar expressions (or the negative versions of such words or expressions) are intended to identify such forward-looking statements. These forward-looking statements include, without limitation, the Company\u2019s goals and commercial plans, the benefits of the Company\u2019s products and services, and the Company\u2019s future performance and its ability to implement its strategy. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from the expected results. Most of these factors are outside of the Company\u2019s control and are difficult to predict. Factors that may cause such differences include, but are not limited to: the success, cost and timing of the Company\u2019s product development and commercialization activities, including the degree that the Swoop\u00ae<\/i> system is accepted and used by healthcare professionals; the impact of COVID-19 on the Company\u2019s business; the inability to maintain the listing of the Company\u2019s Class A common stock on the Nasdaq; the Company\u2019s inability to grow and manage growth profitably and retain its key employees; changes in applicable laws or regulations; the inability of the Company to raise financing in the future; the inability of the Company to obtain and maintain regulatory clearance or approval for its products, and any related restrictions and limitations of any cleared or approved product; the inability of the Company to identify, in-license or acquire additional technology; the inability of the Company to maintain its existing or future license, manufacturing, supply and distribution agreements and to obtain adequate supply of its products; the inability of the Company to compete with other companies currently marketing or engaged in the development of products and services that the Company is currently marketing or developing; the size and growth potential of the markets for the Company\u2019s products and services, and its ability to serve those markets, either alone or in partnership with others; the pricing of the Company\u2019s products and services and reimbursement for medical procedures conducted using the Company\u2019s products and services; the Company\u2019s estimates regarding expenses, revenue, capital requirements and needs for additional financing; the Company\u2019s financial performance; and other risks and uncertainties indicated from time to time in Company\u2019s filings with the Securities and Exchange Commission, including those under \u201cRisk Factors\u201d therein. The Company cautions readers that the foregoing list of factors is not exclusive and that readers should not place undue reliance upon any forward-looking statements, which speak only as of the date made. The Company does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions or circumstances on which any such statement is based.<\/p>\n

\"\"<\/p>\n

View source version on businesswire.com: <\/span>https:\/\/www.businesswire.com\/news\/home\/20250804516616\/en\/<\/a><\/span><\/p>\n

Media Contact
\n<\/b>
Devin Zell
\n
Hyperfine
\n
dzell@hyperfine.io<\/a><\/p>\n

Investor Contact
\n<\/b>
Webb Campbell
\n
Gilmartin Group LLC
\n
webb@gilmartinir.com<\/a><\/p>\n

KEYWORDS:<\/b> United States North America Connecticut<\/p>\n

INDUSTRY KEYWORDS:<\/b> FDA Health Technology Data Management Technology Radiology Managed Care General Health Medical Devices Neurology Artificial Intelligence Clinical Trials Science Software Health Research<\/p>\n

MEDIA:<\/b><\/p>\n\n\n\n\n\n\n\n
Photo<\/b><\/font><\/td>\n<\/tr>\n
\"Photo\"<\/td>\n<\/tr>\n
<\/font><\/td>\n<\/tr>\n
Logo<\/b><\/font><\/td>\n<\/tr>\n
\"Logo\"<\/td>\n<\/tr>\n
<\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"

Hyperfine Achieves Clinical Milestone Ahead of Plan With 100th Patient Enrolled in Neurology Office Study Using the Next-Generation Swoop\u00ae System NEURO PMR study evaluates the clinical utility and patient experience of AI-powered portable MRI in an outpatient setting GUILFORD, Conn.–(BUSINESS WIRE)–Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared AI-powered portable MRI system for the brain\u2014the Swoop\u00ae system\u2014 today announced the successful enrollment of 100 patients in its NEURO PMR (Neurological Evaluation in the Office with Portable MRI) study just 16 weeks after the study initiation, announced on April 15, 2025. This milestone reflects strong clinician enthusiasm for accessible, point-of-care brain imaging and supports Hyperfine’s market expansion into outpatient neurology offices. … <\/p>\n

Continue reading “Hyperfine Achieves Clinical Milestone Ahead of Plan With 100th Patient Enrolled in Neurology Office Study Using the Next-Generation Swoop\u00ae System”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-870089","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nHyperfine Achieves Clinical Milestone Ahead of Plan With 100th Patient Enrolled in Neurology Office Study Using the Next-Generation Swoop\u00ae System - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/hyperfine-achieves-clinical-milestone-ahead-of-plan-with-100th-patient-enrolled-in-neurology-office-study-using-the-next-generation-swoop-system\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Hyperfine Achieves Clinical Milestone Ahead of Plan With 100th Patient Enrolled in Neurology Office Study Using the Next-Generation Swoop\u00ae System - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Hyperfine Achieves Clinical Milestone Ahead of Plan With 100th Patient Enrolled in Neurology Office Study Using the Next-Generation Swoop\u00ae System NEURO PMR study evaluates the clinical utility and patient experience of AI-powered portable MRI in an outpatient setting GUILFORD, Conn.–(BUSINESS WIRE)–Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared AI-powered portable MRI system for the brain\u2014the Swoop\u00ae system\u2014 today announced the successful enrollment of 100 patients in its NEURO PMR (Neurological Evaluation in the Office with Portable MRI) study just 16 weeks after the study initiation, announced on April 15, 2025. This milestone reflects strong clinician enthusiasm for accessible, point-of-care brain imaging and supports Hyperfine’s market expansion into outpatient neurology offices. … Continue reading "Hyperfine Achieves Clinical Milestone Ahead of Plan With 100th Patient Enrolled in Neurology Office Study Using the Next-Generation Swoop\u00ae System"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/hyperfine-achieves-clinical-milestone-ahead-of-plan-with-100th-patient-enrolled-in-neurology-office-study-using-the-next-generation-swoop-system\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-08-04T16:42:59+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20250804516616\/en\/2542054\/4\/NEURO_PMR_Enrollment_Update_Press_Photo.jpg\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hyperfine-achieves-clinical-milestone-ahead-of-plan-with-100th-patient-enrolled-in-neurology-office-study-using-the-next-generation-swoop-system\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hyperfine-achieves-clinical-milestone-ahead-of-plan-with-100th-patient-enrolled-in-neurology-office-study-using-the-next-generation-swoop-system\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Hyperfine Achieves Clinical Milestone Ahead of Plan With 100th Patient Enrolled in Neurology Office Study Using the Next-Generation Swoop\u00ae System\",\"datePublished\":\"2025-08-04T16:42:59+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hyperfine-achieves-clinical-milestone-ahead-of-plan-with-100th-patient-enrolled-in-neurology-office-study-using-the-next-generation-swoop-system\\\/\"},\"wordCount\":1239,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hyperfine-achieves-clinical-milestone-ahead-of-plan-with-100th-patient-enrolled-in-neurology-office-study-using-the-next-generation-swoop-system\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20250804516616\\\/en\\\/2542054\\\/4\\\/NEURO_PMR_Enrollment_Update_Press_Photo.jpg\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hyperfine-achieves-clinical-milestone-ahead-of-plan-with-100th-patient-enrolled-in-neurology-office-study-using-the-next-generation-swoop-system\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hyperfine-achieves-clinical-milestone-ahead-of-plan-with-100th-patient-enrolled-in-neurology-office-study-using-the-next-generation-swoop-system\\\/\",\"name\":\"Hyperfine Achieves Clinical Milestone Ahead of Plan With 100th Patient Enrolled in Neurology Office Study Using the Next-Generation Swoop\u00ae System - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hyperfine-achieves-clinical-milestone-ahead-of-plan-with-100th-patient-enrolled-in-neurology-office-study-using-the-next-generation-swoop-system\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hyperfine-achieves-clinical-milestone-ahead-of-plan-with-100th-patient-enrolled-in-neurology-office-study-using-the-next-generation-swoop-system\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20250804516616\\\/en\\\/2542054\\\/4\\\/NEURO_PMR_Enrollment_Update_Press_Photo.jpg\",\"datePublished\":\"2025-08-04T16:42:59+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hyperfine-achieves-clinical-milestone-ahead-of-plan-with-100th-patient-enrolled-in-neurology-office-study-using-the-next-generation-swoop-system\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hyperfine-achieves-clinical-milestone-ahead-of-plan-with-100th-patient-enrolled-in-neurology-office-study-using-the-next-generation-swoop-system\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hyperfine-achieves-clinical-milestone-ahead-of-plan-with-100th-patient-enrolled-in-neurology-office-study-using-the-next-generation-swoop-system\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20250804516616\\\/en\\\/2542054\\\/4\\\/NEURO_PMR_Enrollment_Update_Press_Photo.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20250804516616\\\/en\\\/2542054\\\/4\\\/NEURO_PMR_Enrollment_Update_Press_Photo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hyperfine-achieves-clinical-milestone-ahead-of-plan-with-100th-patient-enrolled-in-neurology-office-study-using-the-next-generation-swoop-system\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Hyperfine Achieves Clinical Milestone Ahead of Plan With 100th Patient Enrolled in Neurology Office Study Using the Next-Generation Swoop\u00ae System\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Hyperfine Achieves Clinical Milestone Ahead of Plan With 100th Patient Enrolled in Neurology Office Study Using the Next-Generation Swoop\u00ae System - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/hyperfine-achieves-clinical-milestone-ahead-of-plan-with-100th-patient-enrolled-in-neurology-office-study-using-the-next-generation-swoop-system\/","og_locale":"en_US","og_type":"article","og_title":"Hyperfine Achieves Clinical Milestone Ahead of Plan With 100th Patient Enrolled in Neurology Office Study Using the Next-Generation Swoop\u00ae System - Market Newsdesk","og_description":"Hyperfine Achieves Clinical Milestone Ahead of Plan With 100th Patient Enrolled in Neurology Office Study Using the Next-Generation Swoop\u00ae System NEURO PMR study evaluates the clinical utility and patient experience of AI-powered portable MRI in an outpatient setting GUILFORD, Conn.–(BUSINESS WIRE)–Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared AI-powered portable MRI system for the brain\u2014the Swoop\u00ae system\u2014 today announced the successful enrollment of 100 patients in its NEURO PMR (Neurological Evaluation in the Office with Portable MRI) study just 16 weeks after the study initiation, announced on April 15, 2025. This milestone reflects strong clinician enthusiasm for accessible, point-of-care brain imaging and supports Hyperfine’s market expansion into outpatient neurology offices. … Continue reading \"Hyperfine Achieves Clinical Milestone Ahead of Plan With 100th Patient Enrolled in Neurology Office Study Using the Next-Generation Swoop\u00ae System\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/hyperfine-achieves-clinical-milestone-ahead-of-plan-with-100th-patient-enrolled-in-neurology-office-study-using-the-next-generation-swoop-system\/","og_site_name":"Market Newsdesk","article_published_time":"2025-08-04T16:42:59+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20250804516616\/en\/2542054\/4\/NEURO_PMR_Enrollment_Update_Press_Photo.jpg","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hyperfine-achieves-clinical-milestone-ahead-of-plan-with-100th-patient-enrolled-in-neurology-office-study-using-the-next-generation-swoop-system\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hyperfine-achieves-clinical-milestone-ahead-of-plan-with-100th-patient-enrolled-in-neurology-office-study-using-the-next-generation-swoop-system\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Hyperfine Achieves Clinical Milestone Ahead of Plan With 100th Patient Enrolled in Neurology Office Study Using the Next-Generation Swoop\u00ae System","datePublished":"2025-08-04T16:42:59+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hyperfine-achieves-clinical-milestone-ahead-of-plan-with-100th-patient-enrolled-in-neurology-office-study-using-the-next-generation-swoop-system\/"},"wordCount":1239,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hyperfine-achieves-clinical-milestone-ahead-of-plan-with-100th-patient-enrolled-in-neurology-office-study-using-the-next-generation-swoop-system\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20250804516616\/en\/2542054\/4\/NEURO_PMR_Enrollment_Update_Press_Photo.jpg","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hyperfine-achieves-clinical-milestone-ahead-of-plan-with-100th-patient-enrolled-in-neurology-office-study-using-the-next-generation-swoop-system\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/hyperfine-achieves-clinical-milestone-ahead-of-plan-with-100th-patient-enrolled-in-neurology-office-study-using-the-next-generation-swoop-system\/","name":"Hyperfine Achieves Clinical Milestone Ahead of Plan With 100th Patient Enrolled in Neurology Office Study Using the Next-Generation Swoop\u00ae System - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hyperfine-achieves-clinical-milestone-ahead-of-plan-with-100th-patient-enrolled-in-neurology-office-study-using-the-next-generation-swoop-system\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hyperfine-achieves-clinical-milestone-ahead-of-plan-with-100th-patient-enrolled-in-neurology-office-study-using-the-next-generation-swoop-system\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20250804516616\/en\/2542054\/4\/NEURO_PMR_Enrollment_Update_Press_Photo.jpg","datePublished":"2025-08-04T16:42:59+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hyperfine-achieves-clinical-milestone-ahead-of-plan-with-100th-patient-enrolled-in-neurology-office-study-using-the-next-generation-swoop-system\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/hyperfine-achieves-clinical-milestone-ahead-of-plan-with-100th-patient-enrolled-in-neurology-office-study-using-the-next-generation-swoop-system\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hyperfine-achieves-clinical-milestone-ahead-of-plan-with-100th-patient-enrolled-in-neurology-office-study-using-the-next-generation-swoop-system\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20250804516616\/en\/2542054\/4\/NEURO_PMR_Enrollment_Update_Press_Photo.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20250804516616\/en\/2542054\/4\/NEURO_PMR_Enrollment_Update_Press_Photo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hyperfine-achieves-clinical-milestone-ahead-of-plan-with-100th-patient-enrolled-in-neurology-office-study-using-the-next-generation-swoop-system\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Hyperfine Achieves Clinical Milestone Ahead of Plan With 100th Patient Enrolled in Neurology Office Study Using the Next-Generation Swoop\u00ae System"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/870089","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=870089"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/870089\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=870089"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=870089"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=870089"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}